Cancer cells can break down glutathione outside their cell walls to harvest nutrients when surrounding resources are depleted, according to research published in Nature.
The study reveals that certain tumours exploit the compound, which is primarily known for its antioxidant function, as an emergency reserve. By dismantling extracellular glutathione, the cells secure a steady supply of cysteine, an essential amino acid required for cellular survival and metabolic activity.
When surrounding nutrient availability becomes severely restricted, cancer cells deploy specialized surface enzymes called gamma-glutamyltransferases. These enzymes initiate the breakdown of extracellular glutathione, releasing its individual molecular components so the tumour can absorb and utilize them.
Harvesting cysteine under metabolic stress
Cysteine plays a fundamental role in building cellular proteins and maintaining antioxidant balance inside cells. Access to an external supply of cysteine allows cancer cells to sustain crucial biological processes even when operating in nutrient-poor environments.
In laboratory experiments, scientists verified that interfering with this metabolic pathway reduced the amount of available cysteine around the tumour. This disruption successfully restricted tumour growth across specific experimental models.
Glutathione is a naturally occurring tripeptide molecule found abundantly in human tissue, where it acts as a primary cellular defense against oxidative stress. Amino acids such as cysteine are the basic chemical units required for protein synthesis, tissue maintenance, and cellular repair.
Understanding tumour adaptation
The findings shed light on the remarkable metabolic flexibility of malignant tumours when facing adverse microenvironments. Fast-growing tumours often outpace their local blood supply, creating microenvironments low in oxygen and standard nutrients like glucose.
Gamma-glutamyltransferases are membrane-bound enzymes located on the outer surface of cells, normally involved in clearing extracellular peptides. Nature, the peer-reviewed scientific journal where the study was published, frequently features fundamental breakthroughs in cell biology and oncology.
Researchers noted that the study represents basic laboratory science rather than a clinical trial. As a result, blocking glutathione breakdown does not currently represent an established medical treatment for cancer patients.
New avenues for oncology research
However, the work adds a vital piece to the broader field of tumour metabolism research. The study demonstrates that cancer cells do not merely compete with healthy tissue for surrounding nutrients, but actively adapt to repurpose extracellular molecules for unexpected metabolic roles.
Future research will continue to investigate how tumour cells reprogram their metabolic pathways to survive under environmental pressure, which may eventually inform new strategies for therapeutic intervention.
